Blueprint Medicines Corporation (BPMC) Dividend History

Company News

• Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

  Several companies are up for sale, including TV stations, a health marketing agency, and a biotech firm. Post Holdings is acquiring a pasta brand, and Sanofi is buying Blueprint Medicines. Additionally, Alex Jones may have his personal assets sold due to bankruptcy.

  Benzinga

  Featured Companies: BKR
• Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

  Sanofi agreed to acquire Blueprint Medicines for $9.5 billion, including the rare immunology disease medicine Ayvakit and a promising pipeline. The deal will expand Sanofi's rare and immunology portfolios.

  Benzinga

  Featured Companies: NRIX
• NUT Midline Carcinoma Treatment Market Research Report 2023-2024 & 2034: Market Forecast by Treatment, Route of Administration, and End-User Across 5 Regions and 17+ Countries

  The global NUT midline carcinoma treatment market is expected to grow from $21.88 billion in 2023 to $79.38 billion by 2034, driven by increased investment in cancer research, advances in targeted therapy, and growing awareness of rare cancers. North America and Asia Pacific are expected to be the key growth regions.

  GlobeNewswire Inc.

  Featured Companies: ABBV AMGN BMY CCCC GILD LLY MRK ZYME
• Expert Ratings For Blueprint Medicines

  During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 8 5 3 0 1 Last 30D 1 0 0 0 0 1M Ago 0 1 0 0 0 2M Ago 4 2 3 0 1 3M Ago 3 2 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positive shift, the current average has risen by 14.52% from the previous average price target of $101.60. Investigating Analyst Ratings: An Elaborate Study The standing of Blueprint Medicines among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ami Fadia Needham Maintains Buy $130.00 $130.00 Reni Benjamin JMP Securities Maintains Market Outperform $125.00 $125.00 Sudan Loganathan Stephens & Co. Announces Overweight $140.00 - Andrew Berens Leerink Partners Raises Market Perform $97.00 $50.00 Terence Flynn Goldman Sachs Raises Buy $168.00 $121.00 David Lebowitz Citigroup Raises Sell $76.00 $65.00 Andrew Fein HC Wainwright & Co. Raises Buy $135.00 $125.00 Reni Benjamin JMP Securities Raises Market Outperform $125.00 $114.00 Peter Lawson Barclays Raises Equal-Weight $75.00 $70.00 Christopher Raymond Piper Sandler Raises Neutral $104.00 $78.00 Ami Fadia Needham Raises Buy $130.00 $97.00 Ami Fadia Needham Maintains Buy $97.00 $97.00 Andrew Fein HC Wainwright & Co. Maintains Buy $125.00 $125.00 David Nierengarten Wedbush Maintains Outperform $110.00 $110.00 Ami Fadia Needham Maintains Buy $97.00 $97.00 Bradley Canino Stifel Raises Buy $130.00 $120.00 Reni Benjamin JMP Securities Maintains Market Outperform $114.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company ...Full story available on Benzinga.com

  Benzinga
• Assessing Blueprint Medicines: Insights From 16 Financial Analysts

  In the preceding three months, 16 analysts have released ratings for Blueprint Medicines (NASDAQ:BPMC), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 7 5 3 0 1 Last 30D 0 1 0 0 0 1M Ago 0 1 0 0 0 2M Ago 7 3 3 0 1 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $115.5, a high estimate of $168.00, and a low estimate of $75.00. Marking an increase of 19.69%, the current average surpasses the previous average price target of $96.50. Analyzing Analyst Ratings: A Detailed Breakdown A comprehensive examination of how financial experts perceive Blueprint Medicines is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Reni Benjamin JMP Securities Maintains Market Outperform $125.00 $125.00 Sudan Loganathan Stephens & Co. Announces Overweight $140.00 - Andrew Berens Leerink Partners Raises Market Perform $97.00 $50.00 Terence Flynn Goldman Sachs Raises Buy $168.00 $121.00 David Lebowitz Citigroup Raises Sell $76.00 $65.00 Andrew Fein HC Wainwright & Co. Raises Buy $135.00 $125.00 Reni Benjamin JMP Securities Raises Market Outperform $125.00 $114.00 Peter Lawson Barclays Raises Equal-Weight $75.00 $70.00 Christopher Raymond Piper Sandler Raises Neutral $104.00 $78.00 Ami Fadia Needham Raises Buy $130.00 $97.00 Ami Fadia Needham Maintains Buy $97.00 - Bradley Canino Stifel Raises Buy $130.00 $120.00 David Nierengarten Wedbush Maintains Outperform $110.00 - Andrew Fein HC Wainwright & Co. Maintains Buy $125.00 - Ami Fadia Needham Maintains Buy $97.00 - Reni Benjamin JMP Securities Maintains Market Outperform $114.00 - Key Insights: Action Taken: Responding to changing market dynamics ...Full story available on Benzinga.com

  Benzinga